GNPDA2 CRISPR/Cas9 KO Plasmid (h): sc-417433

Overview

Human GNPDA2 (glucosamine-6-phosphate deaminase 2) is a cytosolic enzyme that catalyzes the reversible conversion of glucosamine-6-phosphate to fructose-6-phosphate and ammonium, linking amino sugar metabolism to glycolysis and broader cellular carbon flux. By modulating the hexosamine pathway, GNPDA2 can influence nutrient sensing and protein glycosylation capacity, processes that impact energy homeostasis and metabolic adaptation. Genetic and expression studies have associated GNPDA2 with obesity-related traits and metabolic phenotypes, supporting its relevance in systems biology of adiposity and insulin-responsive tissues. These features make GNPDA2 a useful target for dissecting how amino sugar turnover interfaces with metabolic signaling and cell-state regulation.

GNPDA2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the GNPDA2 gene in human cell lines. Each plasmid in the pool co-expresses a unique sgRNA, targeting a distinct site within the GNPDA2 locus, alongside the Streptococcus pyogenes Cas9 nuclease, and encodes GFP to enable fluorescent identification and enrichment of successfully transfected cells. This multi-guide strategy increases the likelihood of inducing frameshifts or deletions that produce a functional knockout, offering a more robust alternative to single-guide approaches. DSBs induced at multiple sites are resolved through non-homologous end joining (NHEJ) or, when used with the included HDR donor template, homology-directed repair (HDR) at a defined target site within the locus.

When used in conjunction with the RFP-expressing HDR donor, GFP and RFP fluorescence can be used together to distinguish transfected from edited cell populations, streamlining flow cytometry-based sorting and clone selection workflows.

Homology-Directed Repair (HDR) Donor — Puromycin Cassette with RFP Reporter

For applications requiring confirmed, selectable knockout clones, GNPDA2 HDR Plasmid (h) includes an HDR donor construct containing a puromycin resistance cassette (PuroR) and a red fluorescent protein (RFP) reporter, flanked by homology arms specific to a defined GNPDA2 target site.
When co-transfected with GNPDA2 CRISPR/Cas9 KO Plasmid (h):

• The PuroR-RFP cassette integrates at the Cas9 cut site via HDR, disrupting the GNPDA2 open reading frame.
• RFP fluorescence provides an immediate visual indicator of successful integration, enabling fluorescence-based identification or sorting of edited cells prior to or alongside puromycin selection.
• Successfully edited cells are confirmed through puromycin resistance, substantially reducing clone screening burden.
• This selection strategy is ideal for generating stable, clonal KO cell lines for downstream functional studies, drug screening, or model development.

Cre-lox Cassette Removal System

The HDR donor construct features loxP sites flanking the PuroR-RFP selection cassette to allow clean marker removal following clone confirmation. Transient expression of Cre recombinase via the included Cre Vector: sc-418923 excises the cassette, leaving a minimal residual loxP site within the GNPDA2 locus and eliminating potential confounding effects on downstream assays.
This two-step approach:

• Minimizes disruption to local chromatin architecture and neighboring regulatory elements
• Restores a near-native genomic context at the edited locus
• Enables reuse of the puromycin selection strategy in the same cell line for additional edits

Key Features

• gRNA targeting GNPDA2 exon(s) critical for GNPDA2 function
• Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
• HDR donor with puromycin resistance for positive clone selection
• loxP-flanked PuroR cassette with Cre recombinase vector for seamless marker removal
• Supplied ready to use for delivery by transfection

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.